Morbus Behçet und Sarkoidose aus neurologischer Sicht

Die Sarkoidose und der Morbus Behçet sind seltene immunvermittelte Multisystemerkrankungen, die diagnostisch herausfordernd sein können und meist die Zusammenarbeit verschiedener medizinischer Fachdisziplinen erfordern. Dieser Übersichtsartikel soll klinisch tätige Neurologinnen und Neurologen befähigen, beide Erkrankungen, mit aktuellem Hintergrundwissen versehen, zu erkennen, diagnostisch zu sichern und adäquat zu therapieren.

Schlüsselwörter

Morbus Adamantiades-Behçet - Sarkoidose - Neurosarkoidose - Morbus Behçet - Neuro-Behçet

• Literatur

• 1 Behçet H. Über rezidivierende aphthoese, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937; 105: 1152-1157
• 2 Papoutsis NG, Abdel-Naser MB, Altenburg A. et al. Prevalence of Adamantiades-Behcetʼs disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol 2006; 24: S125
• 3 Davatchi F, Chams-Davatchi C, Shams H. et al. Adult Behcetʼs disease in Iran: analysis of 6075 patients. Int J Rheum Dis 2016; 19: 95-103 doi:10.1111/1756-185X.12691
• 4 Altenburg A, Mahr A, Maldini C. et al. Epidemiologie und Klinik des Morbus Adamantiades-Behçet in Deutschland. Ophthalmologe 2012; 109: 531-541 doi:10.1007/s00347-012-2601-4
• 5 Al-Araji A, Kidd DP. Neuro-Behcetʼs disease: epidemiology, clinical characteristics, and management. Lancet Neurol 2009; 8: 192-204 doi:10.1016/S1474-4422(09)70015-8
• 6 Davatchi F, Chams-Davatchi C, Ghodsi Z. et al. Diagnostic value of pathergy test in Behcetʼs disease according to the change of incidence over the time. Clin Rheumatol 2011; 30: 1151-1155 doi:10.1007/s10067-011-1694-5
• 7 International Team for the Revision of the International Criteria for Behcetʼs Disease. The International Criteria for Behcetʼs Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28: 338-347 doi:10.1111/jdv.12107
• 8 [Anonymous] Criteria for diagnosis of Behcetʼs disease. International Study Group for Behcetʼs Disease. Lancet 1990; 335: 1078-1080
• 9 Kalra S, Silman A, Akman-Demir G. et al. Diagnosis and management of Neuro-Behcetʼs disease: international consensus recommendations. J Neurol 2014; 261: 1662-1676 doi:10.1007/s00415-013-7209-3
• 10 Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcetʼs disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999; 122 (Pt 11): 2171-2182
• 11 Yesilot N, Shehu M, Oktem-Tanor O. et al. Silent neurological involvement in Behcetʼs disease. Clin Exp Rheumatol 2006; 24: S65-S70
• 12 Yesilot N, Bahar S, Yilmazer S. et al. Cerebral venous thrombosis in Behcetʼs disease compared to those associated with other etiologies. J Neurol 2009; 256: 1134-1142 doi:10.1007/s00415-009-5088-4
• 13 Siva A, Saip S. The spectrum of nervous system involvement in Behcetʼs syndrome and its differential diagnosis. J Neurol 2009; 256: 513-529 doi:10.1007/s00415-009-0145-6
• 14 Sarui H, Maruyama T, Ito I. et al. Necrotising myositis in Behcetʼs disease: characteristic features on magnetic resonance imaging and a review of the literature. Ann Rheum Dis 2002; 61: 751-752
• 15 Saip S, Siva A, Altintas A. et al. Headache in Behcetʼs syndrome. Headache 2005; 45: 911-919 doi:10.1111/j.1526-4610.2005.05160.x
• 16 Oktem-Tanor O, Baykan-Kurt B, Gurvit IH. et al. Neuropsychological follow-up of 12 patients with neuro-Behcet disease. J Neurol 1999; 246: 113-119
• 17 Lee SH, Yoon PH, Park SJ. et al. MRI findings in neuro-behcetʼs disease. Clin Radiol 2001; 56: 485-494 doi:10.1053/crad.2000.0675
• 18 Mohamed C, Najib K, Essaadouni L. Radiological findings in Behcet disease. Pan Afr Med J 2015; 20: 51 doi:10.11604/pamj.2015.20.51.5928
• 19 Coban O, Bahar S, Akman-Demir G. et al. Masked assessment of MRI findings: is it possible to differentiate neuro-Behcetʼs disease from other central nervous system diseases? [corrected]. Neuroradiology 1999; 41: 255-260
• 20 Akman-Demir G, Tuzun E, Icoz S. et al. Interleukin-6 in neuro-Behcetʼs disease: association with disease subsets and long-term outcome. Cytokine 2008; 44: 373-376 doi:10.1016/j.cyto.2008.10.007
• 21 Saruhan-Direskeneli G, Yentur SP, Mutlu M. et al. Intrathecal oligoclonal IgG bands are infrequently found in neuro-Behcetʼs disease. Clin Exp Rheumatol 2013; 31: 25-27
• 22 Kidd DP. Neurological complications of Behcetʼs syndrome. J Neurol 2017; 264: 2178-2183 doi:10.1007/s00415-017-8436-9
• 23 Patterson KC, Chen ES. The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest 2018; 153: 1432-1442 doi:10.1016/j.chest.2017.11.030
• 24 Facco M, Cabrelle A, Teramo A. et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011; 66: 144-150 doi:10.1136/thx.2010.140319
• 25 Ten Berge B, Paats MS, Bergen IM. et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford) 2012; 51: 37-46 doi:10.1093/rheumatology/ker316
• 26 Hena KM, Yip J, Jaber N. et al. Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters. Chest 2018; 153: 114-123 doi:10.1016/j.chest.2017.10.014
• 27 Izbicki G, Chavko R, Banauch GI. et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007; 131: 1414-1423 doi:10.1378/chest.06-2114
• 28 Sverrild A, Backer V, Kyvik KO. et al. Heredity in sarcoidosis: a registry-based twin study. Thorax 2008; 63: 894-896 doi:10.1136/thx.2007.094060
• 29 Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol 2016; 16: 220 doi:10.1186/s12883-016-0741-x
• 30 Valeyre D, Prasse A, Nunes H. et al. Sarcoidosis. Lancet 2014; 383: 1155-1167 doi:10.1016/S0140-6736(13)60680-7
• 31 Hoitsma E, Marziniak M, Faber CG. et al. Small fibre neuropathy in sarcoidosis. Lancet 2002; 359: 2085-2086
• 32 Zajicek JP, Scolding NJ, Foster O. et al. Central nervous system sarcoidosis–diagnosis and management. QJM 1999; 92: 103-117
• 33 Hoitsma E, Faber CG, Drent M. et al. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3: 397-407 doi:10.1016/S1474-4422(04)00805-1
• 34 Bolat S, Berding G, Dengler R. et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 2009; 287: 257-259 doi:10.1016/j.jns.2009.08.060
• 35 Bathla G, Singh AK, Policeni B. et al. Imaging of neurosarcoidosis: common, uncommon, and rare. Clin Radiol 2016; 71: 96-106 doi:10.1016/j.crad.2015.09.007
• 36 Bathla G, Watal P, Gupta S. et al. Cerebrovascular Manifestations of Neurosarcoidosis: An Underrecognized Aspect of the Imaging Spectrum. AJNR Am J Neuroradiol 2018; 39: 1194-1200 doi:10.3174/ajnr.A5492
• 37 Flanagan EP, Kaufmann TJ, Krecke KN. et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79: 437-447 doi:10.1002/ana.24582
• 38 Voortman M, Drent M, Baughman RP. Management of neurosarcoidosis: a clinical challenge. Curr Opin Neurol 2019; 32: 475-483 doi:10.1097/WCO.0000000000000684
• 39 Siltzbach LE. The Kveim test in sarcoidosis. A study of 750 patients. JAMA 1961; 178: 476-482
• 40 Hottenrott T, Dersch R, Berger B. et al. The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. Fluids Barriers CNS 2015; 12: 27 doi:10.1186/s12987-015-0024-8
• 41 Stern BJ, Griffin DE, Luke RA. et al. Neurosarcoidosis: cerebrospinal fluid lymphocyte subpopulations. Neurology 1987; 37: 878-881
• 42 Nemecek A, Zimmermann H, Rubenthaler J. et al. Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression. Mult Scler 2016; 22: 483-493 doi:10.1177/1352458515593821
• 43 Bridel C, Courvoisier DS, Vuilleumier N. et al. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol 2015; 285: 1-3 doi:10.1016/j.jneuroim.2015.05.020
• 44 Petereit HF, Reske D, Tumani H. et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol 2010; 257: 1855-1863 doi:10.1007/s00415-010-5623-3
• 45 Baughman RP, Drent M, Kavuru M. et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802 doi:10.1164/rccm.200603-402OC
• 46 Cohen Aubart F, Bouvry D, Galanaud D. et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol 2017; 264: 891-897 doi:10.1007/s00415-017-8444-9